Inhibitors of Protein Kinases
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application 61/120,344, filed Dec 5, 2008. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,501,944 | Inhibitors of Protein Kinases In force · High confidence UsedRemaining | Alexion Pharmaceuticals, Inc. | In force | High confidence | ||
| US 8,937,070 | Inhibitors of Protein Kinases In force · High confidence | Alexion Pharmaceuticals, Inc. | In force | High confidence | ||
| US 9,868,729 | Inhibitors of Protein Kinases In force · High confidence | Alexion Pharmaceuticals, Inc. | In force | High confidence | ||
| US 10,533,001 | Inhibitors of Protein Kinases In force · High confidence | Alexion Pharmaceuticals, Inc. | In force | High confidence | ||
| US 11,414,410 | Inhibitors of Protein Kinases In force · High confidence | Alexion Pharmaceuticals, Inc. | In force | High confidence | ||
| US 8,138,339 | Inhibitors of Protein Kinases In force · High confidence | Alexion Pharmaceuticals, Inc. | In force | High confidence |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.